

[Heparin sodium](#)

Essential medicine status

Section:

[10. Medicines affecting the blood](#) [10.2. Medicines affecting coagulation](#)

ATC codes: [B01AB01](#)

EMLc

Indication

Venous thromboembolism ICD11 code: [BD72](#)

INN

Heparin sodium

Medicine type

Chemical agent

List type

Core (EML)

Complementary (EMLc)

Formulations

Parenteral > General injections > IV: 1000 IU per mL in 1 mL ampoule or vial ; 20000 IU per mL in 1 mL ampoule or vial (EML) ; 5000 IU per mL in 1 mL ampoule or vial

EML status history

First added in 1977 ([TRS 615](#))

Changed in 1979 ([TRS 641](#))

Changed in 1982 ([TRS 685](#))

Changed in 2007 ([TRS 950](#))

Changed in 2009 ([TRS 958](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Heparin sodium](#)

DrugBank

[Heparin sodium \(Heparin\)](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - to modify the formulation descriptions to better describe the available dosage forms.